COMT inhibition as a potential therapeutic target among individuals with comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder Save

Date Added
April 2nd, 2019
PRO Number
Pro00086929
Researcher
Joseph Schacht

List of Studies


Profiles_link
Keywords
ADD/ADHD, Alcohol, Drug Studies, Psychiatry
Summary

The purpose of this study is to evaluate the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During two of these visits, participants will undergo a one-hour MRI scan. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD. Compensation is available for qualified participants.

Institution
MUSC
Recruitment Contact
Zoe Brasher
(843) 792-7588
brasherz@musc.edu

A pilot human laboratory study of cannabidiol in Alcohol Use Disorder Save

Date Added
March 5th, 2019
PRO Number
Pro00086168
Researcher
Joseph Schacht

List of Studies


Profiles_link
Keywords
Alcohol, Drug Studies, Psychiatry
Summary

This study will examine the effects of Epidiolex among adults who drink alcohol heavily but who are not seeking treatment for their alcohol use. Epidiolex is an FDA-approved formulation of cannabidiol, the primary non-psychoactive constituent of cannabis. Participants in the study will be randomly assigned to take Epidiolex or placebo for 8 days. There are 3 study visits, including a day-long visit in the laboratory.

Institution
MUSC
Recruitment Contact
Katy Fuqua
(843) 792-1452
fuquama@musc.edu

Change_preferences

-- OR --

Create_login